TMX NewsfileMay 29, 2026 5:04 PM EDT Theralase® Provides an Update on its Phase II Bladder Cancer Clinical Study Toronto, Ontario–(Newsfile Corp. – May 29, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancer, bacteria and viruses has released the Company’s unaudited interim consolidated financial statements for the three-month period ended March 31st, 2026 (“Financial Statements“). Theralase® will be hosting a conference call on June 9th at 11:00 am ET, which will include a presentation of the financial and operational results for the quarter ended March 31st, 2026. To ensure Theralase® has time to address questions during the call, please e-mail them in advance to mperraton@theralase.com. Zoom Meeting Link: https://us02web.zoom.us/j/83115432624 Conference Call in: 1-647-558-0588 (Canada) / 1-646-558-8656 (US) – not required for those attending by Zoom.  An archived … Read More

TMX Newsfile | Jun 3, 2026 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – June 3, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that the TSX Venture Exchange (“TSXV“) has accepted for listing up to 20,399,050 common share purchase warrants of the Company (“Warrants“), bearing the CUSIP: 88337V142, for trading on the TSXV. The Warrants are expected to commence trading on the TSXV at the open of markets on June 9th, 2026, under the trading symbol “TLT.WT“. The Warrants were issued pursuant to a brokered private placement (“Private Placement“) of the Company that closed on May 20th, 2026, in which the Company issued: The Private Placement raised aggregate gross proceeds of C$4,600,000 and included the full exercise … Read More

TMX NewsfileMay 20, 2026 11:06 AM EDT Toronto, Ontario–(Newsfile Corp. – May 20, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has closed its previously announced brokered private placement offering (“Brokered Offering“) of 19,166,667 units (“Units“) of the Company at a price of C$0.24 per Unit (“Offering Price“) for gross proceeds of C$4,600,000; including, the full exercise of the over-allotment option. The Brokered Offering was led by Research Capital Corporation as sole agent and sole bookrunner (“Agent“). In addition, the Company is pleased to announce it has closed a concurrent non-brokered private placement offering pursuant to which the Company issued 673,624 Units at the Offering Price for gross proceeds of C$161,669 (“Non-Brokered Offering“, together with … Read More

TMX Newsfile | May 4, 2026 5:22 PM EDT Toronto, Ontario–(Newsfile Corp. – May 4, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancer, bacteria and viruses has released the Company’s audited consolidated financial statements for the twelve-month period ended December 31st, 2025 (“Financial Statements“). Theralase® will be hosting a conference call on May 12th at 11:00 am ET, which will include a presentation of the financial and operational results for the fiscal year ending December 31st, 2025. To ensure Theralase® has time to address questions during the call, please e-mail them in advance to mperraton@theralase.com. Zoom Meeting Link:  https://us02web.zoom.us/j/82405815948      Conference Call in:  1-647-558-0588 (Canada) / 1-646-558-8656 (US) – not required for those attending by Zoom.   An archived version will be available on the website following … Read More

TMX Newsfile | Apr 13, 2026 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – April 13, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses has demonstrated a complete response of all animals treated with X-Ray-activated Rutherrin® in a preclinical animal model of Muscle Invasive Bladder Cancer (“MIBC“). Kaplan–Meier survival analysis from the orthotopic MIBC animal study demonstrated that 100% of the animals treated with X-Ray-activated Rutherrin® exhibited a complete response and remained cancer-free at the end of the study; whereas, animals assigned to the radiation only or untreated control group did not respond as well. (See Figure 1). Figure 1: Kaplan-Meier Survival Curve Demonstrating Complete Response of Animals Treated with X-Ray-activated Rutherrin® in MIBC Animal Model To view an enhanced version of … Read More

TMX Newsfile | Apr 10, 2026 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – April 10, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has successfully closed both a non-brokered private placement offering (“Offering“) of units (“Units“) and a Line Of Credit (“LOC“). On closing of the Offering, the Corporation issued an aggregate of 6,404,700 Units at a price of $CAN 0.26 per Unit for aggregate gross proceeds of $CAN 1,665,222. Each Unit consisted of one common share of the Company (“Common Share“) and one common share purchase warrant (“Warrant“). Each Warrant entitles the holder to acquire an additional Common Share at an exercise price of $CAN 0.36 per share for a period of 5 years following … Read More

TMX Newsfile | Mar 17, 2026 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – March 17, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company, dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce the discovery of an additional Mechanism Of Action (“MOA“) as to how Ruvidar® is so effective in the inactivation of the Herpes Simplex Virus (“HSV-1“). Theralase® previously reported that Ruvidar® (TLD-1433) was effective in the inactivation of HSV-1 and was superior to the standard of care treatment Acyclovir. See Figure 1.1,2,3 (April 10, 2025 – “Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments” and September 24, 2025 – “Independent Research Demonstrates Ruvidar® Effective in the Destruction of Herpes Simplex Virus“) Figure 1: Anti-viral effect of Ruvidar® versus Acyclovir in HSV-1 (24 hours … Read More

TMX Newsfile | Mar 10, 2026 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – March 10, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has successfully closed a non-brokered private placement offering (“Offering“) of units (“Units“). On closing, the Corporation issued an aggregate of 4,230,770 Units at a price of $CAN 0.26 per Unit for aggregate gross proceeds of $CAN 1,100,000. Each Unit consisted of one common share of the Company (“Common Share“) and one common share purchase warrant (“Warrant“). Each Warrant entitles the holder to acquire an additional Common Share at an exercise price of $CAN 0.36 per share for a period of 5 years following the date of closing. The Company plans to … Read More

TMX Newsfile | Mar 9, 2026 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – March 9, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to present its latest preclinical data demonstrating that X-Ray-activated Rutherrin® is effective in the destruction of Muscle Invasive Bladder Cancer (“MIBC“). In the MIBC preclinical models conducted by the Theralase® research team, Rutherrin® demonstrated an ability to significantly enhance the efficacy of radiation therapy in the destruction of MIBC, supporting its potential as an effective drug for this devastating condition. Approximately 25% of the 83,000+ new bladder cancer cases diagnosed annually in the United States and 13,300+ cases in Canada are MIBC. MIBC carries a significant risk of death that has not changed in decades.1,2 The standard … Read More